2-HYDROXYBENZOIC ACID

WHAT IS 2-HYDROXYBENZOIC ACID?

2-Hydroxybenzoic Acid, also known as Salicylic Acid, o-Hydroxybenzoic Acid, 2-Carboxyphenol and Acidum Salicylicum, is a substituted benzoic acid with a hydroxyl group located next to the carboxylic acid group on the aromatic ring. The number two identifies the ortho position, distinguishing Salicylic Acid from the corresponding meta and para hydroxybenzoic acid isomers. The neighboring functional groups influence acidity and molecular interactions, including the possibility of intramolecular hydrogen bonding.

The ortho arrangement helps explain why 2-Carboxyphenol behaves differently from benzoic acid or an aliphatic hydroxy acid even when each can provide acidity to a formulation. The common name Salicylic Acid appears frequently in ingredient lists, pharmaceutical documentation and laboratory methods, while Acidum Salicylicum is its traditional Latin name. o-Hydroxybenzoic Acid and 2-Hydroxybenzenecarboxylic Acid are useful alternative names in chemical purchasing and technical descriptions. 

2-Carboxyphenol is a discrete free-acid molecule rather than a broad mixture of botanical constituents. A willow-derived extract, a salicylate salt and a salicylic ester should therefore not be accepted as equivalent ingredients simply because they are associated with the same chemical family.

In personal-care development, Salicylic Acid can support a specific exfoliation-related concept when formulated and assessed appropriately. It is not a universal answer to every skin concern, and a raw-material description should not promise the results of an untested finished product. Chemical manufacturers use the same molecule as a starting point for transformations involving its acid or phenolic function.

That role makes the impurity profile and reaction suitability important even when the final product is not a topical formulation. Analytical laboratories may need an SA reference material, with SA denoting Salicylic Acid, carrying a documented value rather than a general-purpose manufacturing grade. The intended use therefore determines what quality evidence is necessary, not merely the percentage printed beside the product name.

COMMON PRODUCT AND CHEMICAL NAMES

- Main systematic name: 2-Hydroxybenzoic Acid.
- Most common product name: Salicylic Acid.
- Positional synonym: o-Hydroxybenzoic Acid.
- Expanded positional name: Ortho-Hydroxybenzoic Acid.
- Alternative systematic name: 2-Hydroxybenzenecarboxylic Acid.
- Functional-group naming alternative: 2-Carboxyphenol.
- Alternative positional description: o-Carboxyphenol.
- Traditional Latin name: Acidum Salicylicum.
- Laboratory abbreviation: SA; define the abbreviation in context.
- Skincare category description: BHA or Beta Hydroxy Acid; not an exclusive chemical identifier.
- Qualified supply descriptions: Salicylic Acid Technical Grade, Pharmaceutical Grade, Cosmetic-Suitable Grade and Analytical Grade.
- Physical-form description: Salicylic Acid Crystalline Powder.
- Separate compound, not a synonym: Sodium Salicylate.
- Separate compound, not a synonym: Methyl Salicylate.
- Separate compound, not a synonym: Acetylsalicylic Acid.
- Separate compound, not a synonym: Capryloyl Salicylic Acid.
- Separate positional isomer: 3-Hydroxybenzoic Acid.
- Separate positional isomer: 4-Hydroxybenzoic Acid.

CAS NO, EC / EINECS NO AND INCI NAME

- Product identity: 2-Hydroxybenzoic Acid.
- Common chemical identity: Salicylic Acid.
- CAS No.: 69-72-7.
- EC / EINECS No.: 200-712-3.
- INCI name: Salicylic Acid.
- Molecular formula: C7H6O3.
- Molecular weight: Approximately 138.12 g/mol.
- Condensed formula: 2-HOC6H4COOH.
- Structural description: Benzene ring bearing adjacent phenolic hydroxyl and carboxylic acid groups.
- Chemical family: Aromatic hydroxycarboxylic acids.
- Carboxylic acid groups: One per molecule.
- Phenolic hydroxyl groups: One per molecule.
- Positional relationship: Ortho substitution.
- Common laboratory abbreviation: SA.
- Identifier limitation: The CAS number does not establish pharmaceutical, cosmetic, food or agricultural suitability.
- Ingredient-label limitation: An INCI name does not replace grade qualification or finished-product assessment.

PHYSICAL AND CHEMICAL PROPERTIES

- Physical state: Solid at normal room temperature.
- Typical high-purity appearance: White or colorless crystals and crystalline powder.
- Technical-grade appearance: May be pale buff or otherwise grade dependent; confirm the agreed specification.
- Molecular weight: Approximately 138.12 g/mol.
- Typical melting interval: Approximately 157–161°C, depending on grade and test method.
- Crystal density reference: Approximately 1.44 g/cm3 at 20°C.
- Bulk density: Depends on particle size, shape and packing; not equivalent to crystal density.
- Water-solubility reference: Approximately 2 g/L at 20°C for a published product reference.
- Solubility qualification: Changes with temperature, pH and the complete solvent system.
- Ethanol behavior: More soluble than in room-temperature water; confirm concentration and temperature for the actual blend.
- Organic-solvent behavior: Solvent specific; do not assume equal solubility in every glycol or oil.
- First acid dissociation constant: pKa approximately 2.97 under commonly referenced aqueous conditions.
- Phenolic dissociation: Occurs at much higher pH than carboxyl dissociation.
- Aqueous saturated-solution pH reference: Approximately 2.4 for one published product reference.
- Theoretical carboxyl acid value: Approximately 406 mg KOH/g for pure material on a one-equivalent basis.
- Neutralization product: Salicylate salt when the carboxyl group is neutralized with a suitable base.
- Characteristic analytical behavior: Can produce a colored complex with iron(III) under appropriate test conditions.
- Thermal processing: Evaluate sublimation and decomposition rather than relying on an unqualified boiling-point claim.
- Flash-point reference: Approximately 157°C in a published supplier reference; use the actual SDS and method for safety decisions.
- Water content or drying loss: Grade-specific quality parameter.
- Related substances: Control according to the intended use and supplier specification.
- Residue on ignition: Grade-specific indicator of inorganic residue.
- Particle size: Relevant to charging, dissolution, dust and suspension behavior.
- Shelf life or retest period: Obtain for the actual supplied grade.

MOLECULAR STRUCTURE AND THE ORTHO POSITION

2-Hydroxybenzoic Acid has an ortho arrangement that places the phenolic hydroxyl group close to the carboxyl group. This proximity allows interactions that are not reproduced simply by mixing phenol with benzoic acid or choosing another hydroxybenzoic acid isomer. Intramolecular hydrogen bonding can influence the balance between molecular association with itself and interaction with the surrounding medium.

The consequence for a formulation depends on the solvent and ionization state rather than one universal structural rule. The aromatic ring of o-carboxyphenol contributes to its nonpolar surface, while the oxygen-containing groups provide polar interaction sites. This combination helps explain its limited room-temperature water solubility and the usefulness of selected organic cosolvents.

The carboxylic acid group is the first function normally neutralized in routine aqueous formulation work. The phenolic hydroxyl remains a separate chemical feature and should not be counted as an equivalent carboxyl group when calculating a mild neutralization charge. At more strongly alkaline conditions, phenolic ionization can become relevant.

Such conditions differ from common topical development, so the simplified one-acid-equivalent calculation should always be connected to the intended pH and analytical method. A substituted aromatic structure also creates routes for derivative manufacture. Esterification, phenolic modification and ring-substitution chemistry each produce materials whose properties must be assessed separately from those of the starting free acid.

These structural details are useful to purchasing teams because they explain why seemingly related materials cannot be substituted by name alone. A salicylate salt can improve aqueous handling, while an ester can change volatility or oil compatibility, but neither is automatically equivalent to the same mass of Salicylic Acid.

SALICYLIC ACID, SALICYLATES AND ESTERS

2-Hydroxybenzoic Acid forms Sodium Salicylate as its sodium salt, which has a different formula mass and solution behavior. It can be useful where a salt is required, but its presence does not mean a formulation contains the same free-acid fraction as one prepared from unneutralized 2-Hydroxybenzoic Acid. Potassium and other salicylate salts introduce different counterions into the product.

Counterion choice affects the mass balance and may influence compatibility, making it a specification issue rather than a cosmetic change in terminology. Methyl Salicylate is an ester with a distinct identity and characteristic odor. It is not a direct substitute for an odorless or low-odor crystalline acid and should not inherit the free acid's formulation instructions.

Acetylsalicylic Acid is formed by modifying the phenolic function and is chemically different from Salicylic Acid. The pharmaceutical significance of acetylsalicylic acid does not make its precursor equivalent in medicinal use or suitable for direct substitution in a drug product. Capryloyl Salicylic Acid is another distinct derivative used in some personal-care discussions.

Its solubility and delivery characteristics require separate evaluation, and the term lipohydroxy acid should not be treated as an alternative identity for unmodified CAS 69-72-7. Other salicylate esters are used in applications ranging from fragrance chemistry to specialized formulation functions. Their purpose depends on the specific structure, and a benefit documented for one ester should not be attributed to every salicylic compound.

Hydroxybenzoic acid positional isomers are also separate molecules. The para isomer, for example, is not Salicylic Acid, so identification should confirm both the functional groups and their position on the ring.

WHAT BHA MEANS IN PERSONAL CARE

2-Hydroxybenzoic Acid, also known as Salicylic Acid, is commonly described as a BHA in skincare terminology. That familiar category name helps users recognize its role, but the exact chemical identity remains the aromatic ortho-hydroxy acid rather than an unspecified family of exfoliating ingredients. The terminology differs from a strictly aliphatic structural description of beta-hydroxy acids.

For technical writing, pairing BHA with the full name avoids implying that every molecule described with the abbreviation is chemically interchangeable. BHA is also used as an abbreviation for butylated hydroxyanisole in other chemical contexts. A purchase inquiry using only those three letters can therefore create a serious identity error, especially when it moves between personal-care and antioxidant discussions.

An ingredient can be associated with an exfoliation concept without establishing a therapeutic claim. Product purpose, wording and the relevant market framework determine whether the finished product is treated as a cosmetic, medicine or another regulated category. The acronym should consequently be used naturally rather than as the sole target of a product page. Technical buyers benefit more from a clear description of Salicylic Acid's concentration, ionization and delivery than from repeated BHA references without formulation context.

ACIDITY, IONIZATION AND THE FREE-ACID FRACTION

2-Hydroxybenzoic Acid has a first pKa of approximately 2.97 under commonly referenced aqueous conditions. Near that pH, the dissolved carboxylic acid and its salicylate form are present in similar proportions in an ideal dilute model. As pH rises, the ionized salicylate fraction increases.

This can help apparent aqueous solubility while changing the proportion of dissolved material present as the uncharged acid. The relationship can be estimated using the Henderson–Hasselbalch expression when its assumptions are appropriate. The salicylate-to-acid ratio is approximately ten raised to the difference between pH and pKa.

At pH 3.5 and pKa 2.97, that simple calculation gives an uncharged acid fraction of approximately 23%. At pH 4.0, it gives about 8.5%, and at pH 5.0 the calculated fraction is less than 1%. Those percentages describe species distribution within the dissolved pool under the model.

They do not establish skin delivery, clinical effect or total dissolved concentration in a complex formulation. Mixed solvents, high ionic strength and phase partitioning can change the practical situation. A formulation containing glycols, surfactants and an oil phase should not be treated as identical to an ideal dilute aqueous solution.

Total o-hydroxybenzoic acid concentration and free-acid fraction are therefore different pieces of information. A product can have a high total assay while containing a relatively small uncharged fraction at its measured pH. Lowering pH is not automatically a performance improvement because tolerability, compatibility and crystallization can become limiting. The appropriate pH window should be established for the complete product and its intended exposure conditions.

WATER SOLUBILITY AND SOLVENT SELECTION

2-Hydroxybenzoic Acid has limited water solubility, which is a central formulation constraint. A target concentration that appears modest on a percentage basis can still exceed the capacity of an acidic room-temperature aqueous vehicle. A published room-temperature water-solubility reference of roughly 2 g/L corresponds only approximately to 0.2% for a dilute water-like system.

That conversion is a useful scale comparison rather than a guaranteed acceptance limit for every water-based product. Ethanol and selected cosolvents can support higher concentrations, but their usefulness depends on the full blend. A mixture containing water, a glycol and surfactants cannot be assigned the pure solvent's solubility without testing.

Temperature can increase dissolution during manufacture and create a misleadingly clear batch. If the product exceeds its stable room-temperature solubility, crystals may appear after cooling or during later storage. Neutralization increases the salicylate fraction and can change apparent solubility.

It also changes the chemical form, so a formulator should not report a neutralized solution as if pH adjustment had no effect beyond clarity. The intrinsic solubility of the uncharged acid differs from the total apparent solubility measured at a particular pH. A simple solubility model uses intrinsic solubility multiplied by an ionization factor, but this model has practical limits in complex vehicles.

Do not insert a published total-solubility value as the intrinsic term without checking its measurement conditions. That mistake can overstate the concentration a formula can hold and lead to avoidable crystallization failures. A development program should examine the actual vehicle at the lowest expected storage temperature as well as at room temperature. This provides a stronger basis for choosing solvent content than observing a warm sample immediately after preparation.

DISSOLUTION, SUPERSATURATION AND CRYSTALLIZATION

2-Hydroxybenzoic Acid dissolution is a kinetic process, while its stable solubility is an equilibrium issue. Fine particles and stronger mixing can make a solid disappear faster without increasing the amount that remains dissolved after equilibration. A clear solution can be supersaturated and persist temporarily before nucleation begins.

Delayed crystal formation is therefore possible even when the initial batch passes a visual clarity check. Cooling, evaporation or a change in pH can move the product outside its stable window. Packaging that allows solvent loss may be particularly relevant when a formulation depends on an organic cosolvent for dissolution.

Crystals can affect texture, dosing and user experience in a topical product. In a manufacturing feed, they can also create line blockage, uneven concentration or filtration losses. Seeded stability testing can help reveal whether a clear solution is robust or merely resistant to initial nucleation.

It should be designed carefully so that the test addresses the actual crystallization risk rather than introducing unrelated contamination. Microscopy can distinguish crystalline material from air bubbles or incompatible droplets. This is useful when haze appears without obvious large particles and the development team needs to identify the failure mechanism.

Reheating may dissolve crystals temporarily but does not necessarily correct the formula. The long-term solution may require a revised solvent balance, lower concentration or another delivery strategy rather than more thermal treatment.

SKINCARE FORMULATION FUNCTIONS

2-Hydroxybenzoic Acid, also known as Salicylic Acid, is associated with exfoliating and keratolytic activity in suitable topical products. A formulation developer should connect that intended function with dissolved state, pH, delivery and the safety assessment of the complete product. Ortho-Hydroxybenzoic Acid is often considered for products addressing surface texture and the appearance of congested or blemish-prone skin.

Such a development concept is different from a guaranteed medical outcome or a claim that every concentration clears pores in every user. Its aromatic structure and ionization behavior distinguish it from highly water-compatible aliphatic hydroxy acids. The resulting delivery characteristics depend on the vehicle rather than an unqualified description that the ingredient dissolves oil.

A leave-on system and a rinse-off system create different exposure conditions. Contact duration, application area and frequency should therefore influence the development brief instead of using one formula for all product categories. Local concentration can change as a topical product dries.

Solvent evaporation, phase redistribution and crystallization should be considered when assessing how the ingredient is presented at the surface after application. The raw-material assay establishes how much acid is charged, but it does not demonstrate consumer benefit or tolerability. Finished-product evidence is needed to support the claims intended for the market.

Appropriate formulation can reduce unnecessary handling or stability problems for the manufacturer. For the end user, the relevant benefit is a product that delivers its supported function consistently without avoidable grit, separation or unsuitable exposure.

FACIAL PRODUCTS AND LEAVE-ON DEVELOPMENT

2-Hydroxybenzoic Acid in a facial formulation needs a vehicle that maintains the intended concentration throughout shelf life. Clear liquids, gels and emulsions each introduce different solubility and distribution issues. For a clear liquid, the solvent package usually receives early attention because visible crystals are an obvious failure.

The team should also evaluate evaporation behavior and packaging, since stability in a tightly closed laboratory vial may not represent consumer use. A gel can slow movement of particles but should not be used to conceal precipitation in a product intended to contain dissolved acid. Clarity, microscopic examination and filtered assay can provide complementary information during development.

An emulsion can distribute the ingredient between phases and interfaces. Total assay alone does not reveal that distribution, making formulation and processing changes relevant even when the nominal acid percentage stays constant. Adult facial development examples should not be generalized to children, large-area body use or oral products.

Those exposures require separate assessment, and the appropriate limits can differ by category and market. The final sensory balance also matters to acceptance. A stable formula that feels excessively drying, sticky or gritty may not satisfy the commercial brief even if its analytical concentration remains correct.

RINSE-OFF CLEANSERS AND SCALP PRODUCT DEVELOPMENT

2-Hydroxybenzoic Acid can be combined with surfactants in rinse-off systems, changing both dissolution and interfacial distribution. A surfactant blend may keep the formula clear while also influencing how much acid is available in different environments during use. Active surfactant content should be calculated separately from the as-supplied ingredient percentage.

Otherwise, two cleanser trials can differ substantially in cleaning intensity while appearing to use the same surfactant loading. Scalp formulations introduce contact conditions and claim considerations different from a simple facial cleanser. Any dandruff, disease or treatment claim should be reviewed within the appropriate medicinal or product framework rather than assumed to be cosmetic everywhere.

Thickening behavior can change when the formulation is acidified. Salt response, polymer compatibility and surfactant structure should be evaluated at the final pH instead of optimized only in the starting unacidified base. Foam is a separate property from the ingredient's desired topical function.

A change in foam after acid addition may reflect surfactant interactions and does not establish a change in biological performance. The product should be assessed after dilution with the expected use water and after the normal rinse sequence. Hardness, contact time and residues can affect the practical result even when the bottled concentrate is stable.

Eye exposure is relevant to facial and hair-cleansing products. Raw-material eye-damage hazards and the finished product's exposure conditions should be addressed through appropriate formulation and safety assessment.

PRESERVATION AND MICROBIOLOGICAL QUALITY

2-Hydroxybenzoic Acid, also known as Salicylic Acid, has a history of use in preservation-related contexts, but a formulated product still requires a complete microbiological strategy. A concentration selected for exfoliation should not automatically be described as an adequate preservative system. Antimicrobial performance can depend on pH and the ingredient's available form.

Binding, partitioning and the surrounding formulation may influence behavior, so a simple total assay does not establish protection against contamination. A broad-spectrum preservation program must address the relevant organisms and package use conditions. This cannot be inferred from a single ingredient's activity or a supplier's general description.

Challenge testing and the applicable microbiological requirements provide evidence for the finished product. Raw-material microbiological quality is another input, particularly where the grade or manufacturing route introduces relevant variability. A low-pH formula is not automatically microbiologically secure.

Consumer contamination, package design and tolerant organisms can still matter, making a finished-product assessment necessary. If the acid is intended specifically as a preservative, that purpose may trigger different concentration rules or documentation from another cosmetic function. The intended role should therefore be stated clearly in the regulatory and formulation brief.

COSMETIC AND MEDICINAL PRODUCT BOUNDARIES

2-Hydroxybenzoic Acid, also known as Salicylic Acid, can appear in a cosmetic ingredient list and in a medicinal active-ingredient context. Product claims, concentration, exposure and the destination market determine the appropriate development and compliance pathway. A therapeutic acne claim should not be attached to a general cosmetic prototype without review.

In the United States, for example, a relevant OTC acne framework specifies Salicylic Acid concentrations and other conditions that extend beyond ingredient identity. A compliant concentration alone does not satisfy every requirement of a drug framework. Manufacturing controls, labeling, dosage form and the other applicable conditions need to be addressed for the actual product.

Cosmetic restrictions can distinguish between purposes, product categories and age groups. A value allowed in one context should not be presented as a universal worldwide maximum or as evidence that an unrelated prototype is safe. Aggregate exposure is important when several products contain the ingredient or related salicylates.

Assessing one bottle in isolation may not address the exposure assumptions used for the intended consumer group. Scientific opinions and legal restrictions serve different roles. A current safety assessment can inform decisions without being identical to the text of a market's binding ingredient restrictions. Because these frameworks can change, the technical page emphasizes lasting formulation principles rather than a frozen global concentration table. The product team should verify the applicable rules at the time of development and market release.

PHARMACEUTICAL MANUFACTURING AND INTERMEDIATE USE

2-Hydroxybenzoic Acid is a recognized starting material for manufacturing acetylsalicylic acid and other salicylic derivatives. Its value in that role comes from controlled chemistry and suitable quality rather than permission to use the raw material as a substitute for the finished medicine. A pharmaceutical manufacturing project should define the relevant compendial or internal requirements before sourcing.

The chemical assay, related substances and manufacturing documentation may all affect acceptance of the proposed grade. Pharmaceutical-grade terminology should identify the actual standard claimed by the supplier. A general statement of high purity does not establish compliance with every pharmacopoeia or every edition of a monograph.

The intended role also matters: an active ingredient, starting material and analytical standard can have different quality requirements. Procurement should not assume that one label covers all three functions. Impurities can affect downstream reaction and purification, even when the incoming material has a high overall assay.

A synthesis route should identify which impurities are transformed, removed or carried into the final product. For acetylsalicylic acid manufacture, the identity of residual Salicylic Acid becomes relevant to the final product's analytical control. The precursor and its acetylated derivative should be measured and discussed as distinct substances.

No medicinal manufacturing recipe or dosing instruction is provided here. A qualified process and appropriate product authorization are necessary before a pharmaceutical material becomes a medicine for use.

SALICYLATE ESTERS AND SPECIALTY CHEMICAL SYNTHESIS

2-Hydroxybenzoic Acid has a carboxyl group that can be converted into an ester using an appropriate reaction route. The alcohol selected determines the organic part of the ester and influences the resulting material's properties. Fragrance-related salicylates, specialized formulation esters and other derivatives should be identified individually.

Their odor, compatibility and exposure profiles cannot be inferred from the free acid alone. The phenolic function creates an additional reaction site that can be modified or protected depending on the target. Selectivity matters because a process intended to modify one function may be affected by reactions involving the other.

Water and inorganic residues can influence synthesis through catalyst behavior, equilibrium and product isolation. A buyer should therefore define the necessary controls for the intended route rather than rely only on the free acid's melting interval. Color-sensitive derivatives may require tighter incoming impurity limits than a general industrial intermediate.

A pale technical powder can be acceptable for one route and unsuitable for another if color develops during reaction. Small-scale synthesis trials should be followed by product analysis and recovery measurements. A clear feed solution and a favorable initial conversion do not establish final derivative quality or purification efficiency.

The resulting ester or modified molecule requires its own SDS and technical specification. Its handling, end-use suitability and commercial claims should not be copied unchanged from a page describing Salicylic Acid.

INDUSTRIAL CHEMISTRY, DYES AND RUBBER COMPOUNDING

2-Hydroxybenzoic Acid in technical grade can serve as an intermediate in selected dye and specialty chemical routes. The relevant advantage is the availability of its specific aromatic and functional-group structure, not a universal improvement in every colored formulation. Dye-intermediate applications require attention to related substances because impurities can change shade, reaction behavior or isolation.

The acceptable impurity profile should be connected to the final colorant specification. Some industrial descriptions include use as a rubber cure retarder in particular systems. Such an application should be evaluated through cure behavior and final compound properties rather than treated as a generic recommendation for all elastomers.

An acid-containing additive can interact with other components in a rubber recipe. Mixing response, scorch behavior and the complete cure package should therefore be tested together before a technical grade is approved. A manufacturing intermediate and a direct formulation additive are different commercial roles.

Salicylic Acid can be useful as the precursor of a material whose ultimate industrial function is not performed by the free acid itself. Avoid assigning the free acid the capabilities of unrelated salicylate additives. Specialized corrosion inhibitors, UV-related ingredients or polymer components may derive from salicylic chemistry while requiring a different molecular structure and validation.

The suitability of a technical grade should be judged against the process brief. It should not be transferred into personal care or medicinal manufacture simply because the same CAS number appears on a higher-quality product.

ANALYTICAL LABORATORIES AND REFERENCE MATERIALS

2-Hydroxybenzoic Acid, also known as Salicylic Acid, can be used in analytical work involving identity, assay and salicylate-related methods. The laboratory should select a material whose documentation supports the intended measurement, rather than assume every high-purity sample is a certified standard. A reference material may require an assigned value, uncertainty and traceability information.

A reagent labeled greater than 99% provides a different evidence package and may be insufficient for the method's calibration requirements. Chromatographic methods can separate Salicylic Acid from related substances when suitably developed. The procedure should demonstrate relevant selectivity, especially where acetylsalicylic acid or other salicylates may be present.

Sample preparation can change composition if the matrix or conditions promote hydrolysis of a derivative. The analyst should verify that measured free acid represents the original sample rather than material generated during preparation. Spectroscopic identity checks can support incoming control but should be matched to the application.

A characteristic functional-group signal may confirm part of the structure without establishing trace-level impurity compliance. The iron(III) color reaction is useful as a qualitative chemical observation under appropriate conditions. It is not a universal quantitative assay and can be affected by concentration, pH and other complexing substances.

Calibration solution concentration should use a clearly stated mass or volume basis. Milligrams per kilogram, milligrams per liter and molarity cannot be exchanged without the necessary preparation and density information.

PLANT SIGNALING AND CONTROLLED RESEARCH

2-Hydroxybenzoic Acid is involved in plant signaling and has been studied in defense and stress-response systems. That biological role makes it useful for controlled research, but it does not establish a universal crop treatment or yield-enhancing recommendation. Experimental outcomes depend on species, growth stage, concentration and exposure method.

A condition associated with a favorable response in one study may produce no benefit or an adverse response in another. Plant signaling networks interact with other pathways, and concentration can change the outcome. More acid should therefore not be assumed to provide stronger protection or better growth.

A laboratory stock solution must distinguish free acid from a neutralized salicylate preparation. Solvent and pH controls are needed so that the observed response is not attributed to the acid when it actually arises from the vehicle or alkalinity. Research trials should include appropriate untreated and vehicle controls.

Replication and predefined endpoints help separate a reproducible biological response from a preparation or environmental difference. Agricultural commercialization requires review of product category, crop safety and applicable authorization. A raw chemical's presence in a research paper does not make an industrial powder an approved pesticide, fertilizer or biostimulant.

No universal foliar dosage is supplied here because the appropriate concentration cannot be determined from chemical identity alone. A responsible development program connects the formulation with species-specific evidence and the intended market framework.

COMPARISON WITH GLYCOLIC, LACTIC AND OTHER EXFOLIATING ACIDS

2-Hydroxybenzoic Acid has a different molecular structure from glycolic and lactic acids, which are aliphatic hydroxy acids. This difference can be useful when the formulation brief requires the particular behavior associated with the aromatic salicylic ingredient. Glycolic acid is highly compatible with aqueous development compared with poorly water-soluble free Salicylic Acid.

A product that must minimize cosolvent content may therefore face a different practical design choice from one focused on a salicylic-acid-specific concept. Lactic acid also introduces acidity and humectancy-related formulation considerations that should not be assigned automatically to o-Hydroxybenzoic Acid. The ingredients can address different product needs even when all are discussed under exfoliation.

Larger or differently structured hydroxy acids may offer another balance of solubility, delivery and tolerability. A general statement that Salicylic Acid is always stronger, gentler or more effective than its alternatives is not technically justified. Concentration alone cannot provide a fair comparison because pKa, vehicle and exposure conditions differ.

A controlled study should define the intended endpoint and account for those differences rather than rank products by their total acid percentage. For pore-appearance or blemish-related development, salicylic-specific evidence may be relevant to the brief. That potential advantage should be connected to the complete finished formulation and intended claim, not converted into a universal medical promise.

The best choice is the ingredient or combination that meets the documented product requirements. Compatibility, stability, safety assessment and cost in use can favor a different acid even when Salicylic Acid remains a valuable candidate.

COMPARISON WITH BENZOIC ACID, SALTS AND DELIVERY ALTERNATIVES

2-Hydroxybenzoic Acid differs from benzoic acid by having an adjacent phenolic hydroxyl function. That creates different acidity, interaction and derivative chemistry, making it useful where those specific features are required. The two aromatic acids should not be substituted solely to match pH.

Equal measured acidity in a finished product does not establish equal solubility, preservation behavior or topical function. Salicylate salts can simplify some aqueous handling situations but change the ingredient's ionization balance. Their advantage depends on whether the process needs a salt or a free-acid delivery concept.

Encapsulated or otherwise formulated salicylic products may offer a different development approach. Their active content, carrier and release behavior must be documented rather than treated as equal to neat crystalline acid on a kilogram basis. A botanical extract can support a different marketing and formulation brief but is not a guaranteed source of the same free-acid concentration.

Standardization should identify which constituents are measured and how they relate to the proposed claim. Particle-size reduction can improve dissolution speed or suspension behavior without increasing equilibrium solubility. It is therefore a processing option rather than a replacement for solvent or ionization design.

Alternative delivery systems should be compared using the complete product's performance and stability. A more convenient supplied form can still introduce carrier incompatibility, analytical complexity or a different regulatory requirement.

SELECTING TECHNICAL, COSMETIC, PHARMACEUTICAL OR ANALYTICAL GRADE

2-Hydroxybenzoic Acid grade selection starts with intended use and the specification needed to support it. A technical intermediate, adult personal-care prototype and pharmaceutical manufacturing material should not be approved against one generic purity threshold. A technical grade may permit a different appearance or impurity profile from a pale, consumer-facing product.

Its suitability depends on whether those differences affect the actual synthesis or industrial process. For personal care, request a grade supported for the proposed application and market. Relevant impurity controls, identity documentation and safety information are more meaningful than an unsupported cosmetic-grade claim.

A pharmaceutical requirement should name the relevant compendial or internal specification. Compliance should be demonstrated for the supplied grade and batch rather than inferred from a reagent purity statement. Analytical applications may need certified reference material rather than manufacturing powder.

The selection should follow the method's traceability and uncertainty requirements. Assay method matters across these categories because titration, chromatography and dry-basis calculation can produce different interpretations. A buyer should ask how the reported value is obtained and what impurities it can distinguish.

Documentation and application testing should be considered together. A grade can meet a broad paper specification while behaving differently in dissolution or color development, making representative qualification worthwhile.

PARTICLE SIZE, BULK DENSITY AND POWDER HANDLING

2-Hydroxybenzoic Acid particle characteristics affect how the crystalline material is transferred and dissolved. Smaller particles can provide greater exposed surface area, while coarse material may behave differently in a feeder or mixing vessel. Fine powder can increase dust and may require additional handling controls.

Its processing convenience should therefore be weighed against charging, housekeeping and exposure considerations. Bulk density describes the packed powder rather than the density of an individual crystal. It influences package volume, hopper behavior and mass delivered by volumetric equipment.

A volumetric dosing device requires validation when particle size or packing changes. The same hopper setting can deliver a different mass after a supply-form change even when the chemical assay is unchanged. Powder can also cake or agglomerate during storage and transport.

Those changes may affect dissolution time without necessarily indicating a change in molecular identity. A receiving specification should include particle-size or handling requirements when the plant depends on them. Otherwise, a chemically acceptable lot may create unexpected charging delays or incomplete dissolution within a fixed batch cycle.

For suspension development, particle distribution has an additional role in texture and sedimentation. The quality target should distinguish an intentionally suspended dosage form from a formula intended to remain fully dissolved.

PROCESS DESIGN AND SCALE-UP

2-Hydroxybenzoic Acid processing requires defining whether the objective is a clear solution, controlled suspension or chemical conversion before choosing the equipment sequence. Those objectives involve different acceptance criteria and should not be combined into one vague instruction to mix until uniform. For dissolution, establish the solvent blend and the final storage conditions first.

A heated laboratory solution is not a sufficient scale-up basis if the finished product later crystallizes at ambient temperature. Order of addition can influence local pH and concentration. Adding acid directly into a sensitive polymer or surfactant system may produce a different result from introducing a compatible premix.

A premix should be evaluated over its actual holding time. It can crystallize or change during a production delay even when it is clear immediately after preparation. Scale-up changes heat transfer and the time required for uniform mixing.

Record vessel geometry, fill level and addition rate so that a successful laboratory procedure can be interpreted at production scale. Avoid relying on high shear to correct a thermodynamic solubility problem. Stronger mixing can disperse solids more effectively while leaving the formula vulnerable to later precipitation.

Transfer lines, filters and pumps can create additional losses or concentration differences. A sample taken before transfer may not represent the material that reaches the filling equipment. The final release decision should connect analytical assay with physical state. A complete batch containing the correct total acid may still be unsuitable if part of that acid is present as unintended crystals.

NEUTRALIZATION AND MASS-BALANCE CALCULATIONS

2-Hydroxybenzoic Acid consumes one mole of sodium hydroxide per mole of pure acid during routine conversion of its carboxyl group to sodium salicylate. The molecular weights provide a theoretical sodium hydroxide requirement of approximately 0.290 kg per kilogram of Salicylic Acid. Potassium hydroxide has a different molecular weight and requires approximately 0.406 kg per kilogram of pure acid on the same one-equivalent basis.

The two bases cannot be substituted at equal mass while maintaining the same neutralization balance. For a 100 kg charge of pure 2-Hydroxybenzoic Acid, the theoretical sodium hydroxide mass is approximately 28.96 kg. A 10% sodium hydroxide solution would contain that amount in approximately 289.6 kg of solution, which also introduces substantial water to the process.

Actual assay, reagent concentration and other acidic ingredients should be included in the calculation. If the process deliberately targets partial neutralization, the required charge differs from a complete one-equivalent conversion. Neutralization also changes the product mass because the resulting salt includes the counterion.

Sodium salicylate has a higher formula mass than the free acid, so equal kilograms do not contain equal moles of the salicylic moiety. The reaction generates water when sodium hydroxide is used. That contribution should be recognized alongside the water carried by the base solution rather than ignored in a concentrated intermediate mass balance.

These calculations do not establish the final pH of a complex formulation. Buffering, ionic strength and the other ingredients can affect the measured result, making endpoint verification necessary. A good batch sheet distinguishes charged free acid, neutralizing reagent and calculated salt contribution. This helps purchasing, production and quality teams discuss the same composition without confusing free-acid percentage with acid equivalents.

STARTING FORMULATIONS FOR INDUSTRIAL AND FORMULATION DEVELOPMENT

2-Hydroxybenzoic Acid is used in the following unvalidated laboratory starting points, which are not consumer recipes or approved medicinal products. All ingredient percentages are by mass as supplied and total 100%, with any later pH or composition adjustments requiring a revised final balance. Personal-care examples are intended for qualified adult-product development and require market-specific regulatory and finished-product safety review.

They are not recommendations for children, oral use, aerosol delivery, large-area treatment or direct application of laboratory mixtures. Use suitable ingredient grades and verify dissolution, stability and the intended physical state before progressing. A listed Salicylic Acid percentage does not establish effective delivery, preservation, tolerability or a permitted product claim.

FORMULATION A: HYDROALCOHOLIC FACIAL-VEHICLE SCREEN

- Deionized water: 65.70%.
- Ethanol grade suitable for the intended development: 20.00%.
- Qualified propanediol: 10.00%.
- Glycerin: 3.00%.
- Suitable Salicylic Acid grade: 0.50%.
- Compatible preservation package: 0.80%.
- Total: 100.00%.

This vehicle screens dissolved acid in a mixed solvent environment rather than claiming that 0.5% remains stable in every such blend. Confirm the actual ethanol concentration, cosolvent quality and compatibility of the preservation package. Develop a controlled incorporation sequence that avoids unnecessary evaporation and verify the final physical state after equilibration.

Any pH adjustment changes ionization and must be included in the reformulated mass balance. Assess clarity at the intended storage temperatures and after simulated package use. A product that remains clear in a sealed laboratory vial may crystallize after solvent loss from a different package.

The final development decision should include exposure and sensory assessment in addition to assay. Neither the solvent package nor the acid concentration establishes a finished cosmetic or therapeutic claim by itself.

FORMULATION B: LOW-ACID HYDROALCOHOLIC GEL SCREEN

- Deionized water: 70.10%.
- Qualified propylene glycol: 15.00%.
- Ethanol suitable for the development: 10.00%.
- Glycerin: 3.00%.
- Suitable 2-Hydroxybenzoic Acid grade: 0.50%.
- Qualified compatible hydroxyethylcellulose: 0.60%.
- Compatible preservation package: 0.80%.
- Total: 100.00%.

Select a hydroxyethylcellulose grade that supports the intended solvent and pH conditions. Hydration order should follow the polymer's requirements while allowing the acid to be incorporated through a demonstrated compatible approach. The purpose of the gel is controlled texture, not concealment of undissolved Salicylic Acid.

Examine the sample microscopically and verify that the chosen vehicle maintains the intended dissolved concentration. Measure viscosity after equilibration and storage rather than only during preparation. Changes in solvent content or polymer hydration can alter the result without changing the total acid assay.

Before any human-use development, complete the necessary product assessment and market review. This prototype is not a validated acne drug or a ready-to-use treatment gel.

FORMULATION C: RINSE-OFF CLEANSER COMPATIBILITY SCREEN

- Deionized water: 58.20%.
- Qualified cocamidopropyl betaine solution, approximately 30% active: 18.00%.
- Qualified decyl glucoside solution, approximately 50% active: 12.00%.
- Qualified propanediol: 10.00%.
- Suitable Salicylic Acid grade: 0.50%.
- Compatible hydroxyethylcellulose: 0.50%.
- Compatible preservation package: 0.80%.
- Total: 100.00%.

The supplied surfactant concentrations give an illustrative total active surfactant contribution of approximately 11.4%. Actual assay, carried salts and the selected grades should be used for the final calculation. Evaluate the acid in the complete surfactant vehicle because micellar behavior and pH can affect both clarity and distribution.

Thickening should be optimized at the final composition rather than in an unacidified base. Test dilution, foam and rinsability with the expected use water. Product safety and eye-exposure assessment remain necessary even when the formula is intended to be rinsed away.

Any claim concerning acne, disease or scalp treatment requires the appropriate review for the destination market. A clear cleanser with the stated ingredient percentage does not establish medicinal status or efficacy.

FORMULATION D: ADULT FACIAL-EMULSION DEVELOPMENT SCREEN

- Deionized water: 70.70%.
- Qualified propanediol: 8.00%.
- Qualified caprylic/capric triglyceride: 6.00%.
- Qualified squalane: 4.00%.
- Acid-compatible emulsifier system as supplied: 4.00%.
- Qualified cetearyl alcohol: 3.00%.
- Glycerin: 3.00%.
- Suitable o-Hydroxybenzoic Acid grade: 0.50%.
- Compatible preservation package: 0.80%.
- Total: 100.00%.

Choose an emulsifier system documented for the intended acidic environment and process. The example is a facial-emulsion screen, not a large-area body-lotion or children's product recommendation. Establish how the acid is introduced and whether it remains dissolved or intentionally distributed in a defined phase.

Avoid assuming that an opaque emulsion has solved a crystallization problem simply because particles are difficult to see. Evaluate microscopy, separation, viscosity and acid assay during storage. The oil package and emulsifier can change ingredient distribution, so the same total acid percentage does not guarantee the same behavior as a clear liquid.

Safety, claims and regulatory suitability require assessment of the complete formula. Any pH adjustment or added component should be reflected in a revised 100% composition before further qualification.

FORMULATION E: ETHANOLIC SYNTHESIS-FEED COMPATIBILITY SCREEN

- Ethanol selected for the intended industrial route: 90.00%.
- Qualified 2-Hydroxybenzoic Acid: 10.00%.
- Total: 100.00%.

This blend is an industrial feed-solution screen rather than a complete esterification or pharmaceutical synthesis recipe. Its purpose is to evaluate dissolution, handling and feed consistency in an explicitly selected solvent. Confirm solubility across the required temperature range and during the expected hold period.

A warm clear solution should not be accepted if it later crystallizes in the feed tank or transfer line. Review flammability, equipment and ventilation for the complete solution. The solid acid's thermal references do not define a safe handling temperature for an ethanol-containing blend.

Any subsequent reaction requires its own stoichiometry, catalyst selection and validated process. The solvent may participate in some reaction conditions, so feed compatibility does not establish selectivity or final derivative quality.

FORMULATION F: SODIUM SALICYLATE INTERMEDIATE SCREEN

- Deionized water: 80.52%.
- Sodium hydroxide solution, 10% by mass: 14.48%.
- Qualified Salicylic Acid: 5.00%.
- Total: 100.00%.

The base charge approximates one-equivalent carboxyl neutralization for pure acid using the stated reagent concentration. Actual assays, rounding and other constituents require verification, so the final charge should be established through a controlled endpoint study. Use an appropriate dilution and addition procedure with mixing and temperature monitoring.

The resulting material is a sodium salicylate-containing intermediate rather than a 5% free-acid solution. The theoretical salt contribution is approximately 5.80% before practical assay and composition corrections. Report that distinction clearly when the solution is transferred to another manufacturing or laboratory operation.

This example is not a medicinal dosing formulation, cosmetic shortcut or approved crop treatment. Confirm the specification and intended role of the intermediate before use.

FORMULATION G: MASS-BASED ANALYTICAL WORKING-SOLUTION SCREEN

- Ethanol suitable for the analytical method: 40.00%.
- Water suitable for the analytical method: 59.90%.
- Qualified Salicylic Acid reference material or reagent, as required: 0.10%.
- Total: 100.00%.

The nominal acid concentration is 1,000 mg/kg of complete solution before correcting for the assigned purity. It is not automatically 1,000 mg/L because the solvent mixture's density and preparation basis differ from pure water. Select the material according to the method's traceability requirements and use a validated preparation procedure.

A manufacturing powder may be inappropriate where a certified reference value is required. Verify clarity and solution stability over the intended analytical period. Dilution solvents should remain compatible with the instrument and method, including any chromatographic mobile-phase requirements.

Subsequent calibration levels require documented calculations and suitable dilution technique. The example supports method-development discussion rather than replacing a validated analytical protocol.

FORMULATION H: PLANT-SIGNALING RESEARCH STOCK

- Ethanol selected for the controlled experiment: 99.86188%.
- Qualified 2-Hydroxybenzoic Acid: 0.13812%.
- Total: 100.00000%.

On the stated mass basis and assuming pure acid, this stock contains 10 mmol of Salicylic Acid per kilogram of solution. It should not be labeled 10 mM without a corresponding volumetric preparation and the necessary density information. Use this only as a research stock whose later dilution is defined by the experimental protocol.

Vehicle controls must match the ethanol contribution so that plant responses are not attributed incorrectly to the acid. The working concentration depends on species, endpoint and exposure method, and no universal crop dose follows from the stock composition. Check pH and compatibility of the final research medium as part of the study design.

Agricultural use or commercialization requires separate review of authorization and crop safety. A controlled signaling experiment does not establish an approved pesticide, fertilizer or biostimulant product.

BUILDING A SOLUBILITY AND FORMULATION SCREEN

2-Hydroxybenzoic Acid solubility screening should begin with a solvent matrix that represents realistic commercial options rather than a single optimistic blend. Compare water content, cosolvent type and acid loading while holding the other major variables constant. Prepare an appropriate control without the acid to identify changes caused by the vehicle itself.

This is particularly useful when sensory, viscosity or biological observations could arise from ethanol, glycols or pH adjustment. Record the temperature and time required for dissolution, then evaluate the sample after a defined equilibration period. Those two stages separate process convenience from the stable state needed for storage.

Measure pH using a procedure appropriate to the formulation. Mixed solvents and emulsions may require a defined method so that values can be compared meaningfully between trials. Examine samples at relevant low and elevated temperatures without relying on one acceleration condition.

Different failure mechanisms can appear during cooling, warming and evaporation. Important results should be replicated using independent preparation. This helps establish whether the formulation window is robust or sensitive to small handling differences.

After selecting promising vehicles, introduce the actual packaging and manufacturing sequence. A formula should be qualified after filling and representative use conditions rather than only as a laboratory beaker sample.

ASSAY, RELATED SUBSTANCES AND METHOD SELECTION

2-Hydroxybenzoic Acid assay establishes an amount under a defined analytical procedure, but it does not always identify every impurity. Acidimetric titration measures relevant acidity, while a suitably developed chromatographic method can provide additional chemical selectivity. A supplier result should state whether it is reported as supplied, on a dried basis or on an anhydrous basis.

These distinctions matter when calculating a production charge from the delivered mass. Related-substance testing can address compounds that are not adequately distinguished by a broad assay. Phenol, positional isomers or other process-related constituents may require specific controls according to grade and application.

A high total assay does not prove that a material meets a pharmaceutical impurity profile. The relevant monograph or internal specification should determine which additional tests are necessary. Residue on ignition provides information about inorganic residue, but it does not identify every possible element.

Element-specific limits may be required where the intended use demands them. Water testing and loss on drying are also different measurements. A drying procedure can include volatile matter besides water, so one result should not be substituted for another without understanding the method.

For clear personal-care products, color and insoluble matter can be practical acceptance parameters. A material may pass a chemical assay and still create an appearance problem in a sensitive vehicle. Application testing should complement incoming analysis when processing behavior matters. Comparing dissolution and crystal formation in a reference vehicle can reveal differences not captured by a short certificate of analysis.

STABILITY AND DEGRADATION ASSESSMENT

2-Hydroxybenzoic Acid raw-material stability and finished-product stability should be assessed separately. A crystalline acid can remain within its specification while a formulated product fails through precipitation, packaging interaction or phase redistribution. Physical stability is often the first concern in water-containing Salicylic Acid formulations.

Track clarity, microscopic crystals, sediment and viscosity alongside chemical assay to avoid overlooking an important failure. A stability-indicating method is valuable when chemical change is a realistic concern. The procedure should distinguish the acid from relevant degradation or reaction products rather than report a broad response as unchanged concentration.

In a system containing acetylsalicylic acid or another hydrolyzable salicylate derivative, free Salicylic Acid may increase as the derivative changes. That situation should not be confused with stability of a formula that contains the free acid as its original ingredient. Light, temperature and contacting materials can affect the complete formulation through different routes.

The test design should reflect the actual package and product conditions rather than assume the raw material's storage recommendation covers every vehicle. Evaporation can alter solvent capacity without degrading the acid chemically. An unchanged total assay therefore does not rule out precipitation or a change in the ingredient's dissolved fraction.

Shelf-life conclusions should be supported by an appropriate stability program. A short favorable screen or an arbitrary accelerated period does not automatically establish years of acceptable performance.

PACKAGING AND DISPENSING COMPATIBILITY

2-Hydroxybenzoic Acid formulation packaging influences solvent retention, contamination and delivery of the finished formulation. A product dependent on a particular cosolvent ratio needs a package that preserves that ratio adequately over the intended use period. Closure and seal materials should be assessed with the complete formula.

Compatibility of the main bottle does not establish that every gasket, liner or pump component behaves acceptably. A gel or emulsion should dispense consistently after storage and temperature exposure. Changes in viscosity or crystal formation can cause uneven dosing even when the bulk appearance is acceptable.

For products intended to remain dissolved, deposits around an opening can indicate local evaporation and concentration. Investigate whether that condition affects cleanliness, user experience or the dose delivered during later use. An opaque package can limit light exposure but also makes visual inspection of crystals more difficult.

Stability testing should therefore examine the contents directly rather than rely only on external package observations. A laboratory jar does not necessarily represent the final product's headspace or opening frequency. Include representative package-use testing when those conditions could affect the formulation.

Powder packaging requires a different focus on moisture, contamination and handling integrity. The supplier's original packaging recommendations should be considered when selecting transfer containers or partial-use storage.

TROUBLESHOOTING COMMON FORMULATION PROBLEMS

2-Hydroxybenzoic Acid crystals appearing after cooling usually indicate that the stable solvent capacity has been exceeded or that the process created a supersaturated solution. Check concentration, pH and the complete solvent balance before increasing manufacturing temperature. Haze can arise from crystals, incompatible droplets or interactions with another ingredient.

Microscopy and appropriate analytical checks help identify the cause rather than treating every cloudy sample as insufficiently mixed. A gel losing viscosity after acid addition may reflect the polymer's pH sensitivity or the electrolyte introduced through adjustment. Optimize the polymer in the final formula rather than selecting it solely from its behavior in water.

Unexpected color can involve impurities or contact with metals under suitable complexing conditions. Compare raw-material retention samples, water quality and equipment contact before blaming the acid assay. A clear product with an unexpectedly different pH requires a review of neutralization and buffering.

Small differences in base concentration or other acidic ingredients can affect species distribution without changing the nominal acid charge. Poor preservation despite an acidic formula should trigger a complete microbiological review. Low pH and Salicylic Acid content do not establish a validated broad-spectrum preservation system.

Sensory irritation or unacceptable dryness cannot be diagnosed from concentration alone. The exposure, vehicle and other ingredients need to be included in the product assessment. For synthesis, unexpected yield or color should be investigated using the actual impurity profile and reaction records. A higher nominal purity is not a universal correction if the limiting factor lies in catalyst, water or process control.

INCOMING SAMPLING AND LOT QUALIFICATION

2-Hydroxybenzoic Acid sampling should represent the delivered batch and minimize contamination. Powder segregation, fines and package handling can affect whether a small laboratory sample reflects the material actually charged to production. Use a documented procedure that identifies the containers sampled and the way a composite is prepared.

Retain individual samples where the quality program requires investigation of package-to-package variation. Incoming checks should focus on the parameters that matter to the intended use. Identity, assay, water and related substances may be central, while particle characteristics or appearance can be equally important to the plant's process.

A certificate of analysis supports release but does not eliminate supplier qualification. Decide which results can be accepted from the producer and which require routine or periodic verification. Retain approved-lot samples under suitable conditions so that later problems can be investigated.

Comparison with an earlier successful lot helps distinguish a material change from a formulation or equipment change. Trend data should use a consistent method basis. Mixing dried-basis assay with as-supplied values can create an apparent quality shift that does not reflect an actual chemical difference.

Supplier change control should address the source, specification and manufacturing details relevant to the application. An unchanged chemical name does not guarantee unchanged dissolution behavior or impurity profile.

TDS, SDS, COA AND QUALITY DOCUMENTATION

2-Hydroxybenzoic Acid technical data sheets should describe the actual grade, physical form and relevant reference properties. Guaranteed release limits should be distinguished from typical values so that purchasing can establish a clear acceptance basis. The safety data sheet addresses hazards and handling for the supplied product.

Review the current document for the delivery market rather than assuming a general organic-acid SDS covers Salicylic Acid adequately. The certificate of analysis should connect a batch number with reported quality results. Clarify whether each entry is measured for the lot, calculated or listed as a specification statement.

For a pharmaceutical project, request the documented standard claimed by the supplier and the necessary supporting information. Compliance should be reviewed for the actual material rather than inferred from a familiar pharmacopoeia abbreviation in a sales description. For personal care, obtain the INCI identity and any available application-suitability documentation.

These records support the assessment but do not replace evaluation of the complete finished product. Composition, origin and impurity declarations may be needed for customer-specific requirements. Request documents relevant to the intended use rather than assume every possible certificate is available or meaningful.

Ataman Kimya can be contacted to request the documents available for the proposed Salicylic Acid supply. Grade availability, document scope and batch-specific data should be confirmed for the actual offer. Compare the name, CAS number and grade across the quotation, TDS, SDS and COA before approval. A mismatch involving a salt, ester or positional isomer should be resolved before the material enters the process.

SAFE HANDLING AND WORKPLACE EXPOSURE

2-Hydroxybenzoic Acid, also known as Salicylic Acid, requires handling based on its actual SDS, not on the assumption that a familiar skincare ingredient is harmless as a raw powder. Supplier classifications can include harmful ingestion, serious eye damage and suspected harm to the unborn child, which are relevant to workplace assessment. Powder transfer can generate airborne material and contamination at the charging point.

Use appropriate containment, ventilation and task-specific protective measures to reduce avoidable exposure. Eye protection is particularly important where dust or splashes from solutions could reach the face. Equipment design and sampling procedures should address those opportunities rather than depend only on operator attention.

Glove selection should consider both the acid and any solvent used in the process. A glove suitable for a dry powder may not provide the same protection against an ethanol-containing or other solvent mixture. Neutralization introduces the hazards of the selected base and the heat of reaction.

The process assessment should cover addition control, mixing and the response to equipment interruption. Heated handling requires review of sublimation, decomposition and hot-surface exposure. A melting interval should not be treated as a routine instruction to melt the acid for every formulation.

Solvent-based trials need separate fire and vapor controls for the complete mixture. The thermal references of the solid cannot establish safe operation of a flammable solution. First-aid and spill procedures should follow the supplied SDS and local workplace arrangements. In particular, eye exposure should be treated promptly according to the emergency guidance rather than dismissed as ordinary irritation.

STORAGE, PACKAGING AND POWDER CONDITION

2-Hydroxybenzoic Acid should be stored in closed packaging under the supplier's recommended conditions. Keep the material protected from contamination and unnecessary moisture so that the grade remains suitable for its intended use. A cool, dry storage environment helps preserve powder handling quality.

Temperature recommendations should come from the supplied material's documentation rather than a universal value copied across all grades. Segregate from incompatible substances identified in the SDS. Strong bases are particularly relevant to the acid function, and unintended contact can produce material that no longer meets the original free-acid specification.

Opened containers should be resealed and clearly identified. Traceability should remain intact when part of a package is moved to a feeder, day bin or smaller working container. Caking can affect charging and dissolution even when chemical assay remains acceptable.

Inspect older or damaged packages and test as necessary before introducing them into a process with a fixed dissolution cycle. Stock rotation and recorded receipt or opening dates can support quality management. The supplier's shelf-life or retest recommendation should be used for the actual grade rather than inventing a period from the chemical name.

For bulk or larger-package deliveries, assess sampling and transfer cleanliness. A change in packaging format can create different operational risks even when the chemical specification is unchanged.

APPLICATION BOUNDARIES

2-Hydroxybenzoic Acid food use should not be inferred from historical preservation references or general chemical catalogs. A specific food-related project requires confirmation of the exact permitted use and suitable grade in the intended market. Veterinary and agricultural products likewise require their own review.

The fact that a molecule is studied in a biological system does not establish an approved product for animals or crops. Industrial synthesis may produce derivatives whose exposure profiles differ from the starting acid. Each resulting material requires its own identity and suitability assessment.

A clear boundary between established functions and proposed uses improves technical decision-making. Buyers can then focus on the chemistry relevant to their process without relying on unsupported claims from another industry.

COST IN USE AND SUPPLIER COMPARISON

2-Hydroxybenzoic Acid delivered price per kilogram is only one part of the sourcing decision. Dissolution time, impurity-related rework and finished-product rejection can outweigh a modest difference in the purchase price of Salicylic Acid. For synthesis, compare useful molar content and the impurity profile that affects the route.

A material with a slightly higher assay may still be less suitable if its related substances create a difficult purification burden. For personal care, a consistent pale grade can reduce appearance and stability uncertainty. That value should be demonstrated in the reference vehicle rather than assumed from a general premium-quality description.

Physical form can influence charging accuracy and labor. A fine powder may dissolve faster but demand stronger dust control, while coarser material may suit a particular feeder better. Documentation and traceability can reduce qualification delays when they address the actual application requirements.

Their commercial value depends on the supplied records, not on an unsupported promise of every certificate. A fair supplier comparison uses the same analytical basis and acceptance criteria. Otherwise, a lower quote may appear attractive because it omits tests or packaging requirements included in another proposal.

Application qualification should remain part of a source change when the process is sensitive. A successful paper comparison does not establish identical crystallization, color development or downstream reaction behavior.

PREPARING A TECHNICAL PURCHASE INQUIRY

2-Hydroxybenzoic Acid should be identified by its main name or Salicylic Acid and CAS No. 69-72-7 in a technical purchase inquiry. Avoid using BHA or salicylate alone when a salt, antioxidant or derivative could be confused with the required free acid. Describe the intended role, such as adult personal-care development, pharmaceutical intermediate manufacture or analytical use.

This allows the supplier to discuss appropriate grades without requiring a confidential complete formula. Specify the required standard and assay basis where these are known. Add limits for related substances, water, residue or appearance according to the process rather than copying an unrelated specification.

State the preferred physical form and any particle-size or handling constraints. Those details help ensure that a chemically correct delivery also suits the plant's charging and dissolution equipment. Request the TDS, SDS and relevant COA, together with necessary application-specific declarations.

Ask which tests are performed per batch and how changes to the source or specification are communicated. Provide quantity, packaging preference, delivery destination and project timing. Actual availability, lead time and commercial conditions should be confirmed through a specific offer.

For replacement qualification, share the performance criteria that must remain comparable. A defined dissolution, impurity or finished-product requirement creates a more useful discussion than a request for unspecified equivalent quality.

FREQUENTLY ASKED QUESTIONS ABOUT 2-HYDROXYBENZOIC ACID

Is 2-Hydroxybenzoic Acid the same as Salicylic Acid?
Yes, the names identify the same free-acid molecule. Confirm CAS No. 69-72-7 when reviewing a proposed supply.

What are its common synonyms?
Salicylic Acid, o-Hydroxybenzoic Acid and Ortho-Hydroxybenzoic Acid are common alternatives. 2-Hydroxybenzenecarboxylic Acid and 2-Carboxyphenol also describe the same structure.

What is the CAS number?
The CAS number is 69-72-7. It should not be replaced by the identifier of a salicylate salt or ester.

What is the EC / EINECS number?
The EC / EINECS number is 200-712-3. This identifier does not establish application grade or regulatory approval.

What is the INCI name?
The INCI name is Salicylic Acid. Cosmetic use still requires a suitable grade and assessment of the finished product.

What is its molecular weight?
The molecular weight is approximately 138.12 g/mol. The molecular formula is C7H6O3.

Why is it called an ortho-hydroxy acid?
The hydroxyl group occupies the position adjacent to the carboxyl group on the aromatic ring. That relationship distinguishes it from the meta and para isomers.

Is BHA a complete chemical identity?
No, BHA is context-dependent shorthand. Use the full name because the abbreviation also has other chemical meanings.

Is it the same as Acetylsalicylic Acid?
No, acetylation produces a separate compound. Salicylic Acid is a precursor with a different chemical identity and use profile.

Is Sodium Salicylate an equivalent ingredient?
It is the sodium salt rather than the free acid. Equal mass does not provide equal moles or the same solution behavior.

Is Methyl Salicylate the same material?
No, it is an ester with different properties and identity. Its formulation instructions should not be copied to the crystalline free acid.

Is willow extract equivalent to pure Salicylic Acid?
A botanical extract has a different composition and standardization basis. It should not be assumed to provide the same free-acid concentration.

Does Salicylic Acid dissolve readily in room-temperature water?
Its water solubility is limited. The actual concentration must be evaluated with pH, temperature and the complete vehicle.

Can warming solve every solubility problem?
Warming can improve dissolution during preparation without ensuring stability after cooling. Test the finished product under its expected storage conditions.

Why do crystals appear after a clear batch is made?
The sample may be supersaturated or may lose solvent during storage. Changes in temperature or pH can also move it outside the stable window.

Does smaller particle size increase equilibrium solubility?
Smaller particles can improve dissolution speed. They do not automatically increase the stable concentration the vehicle can hold.

What is the first pKa?
A commonly referenced aqueous value is approximately 2.97. The practical ionization balance in a complex formula can differ from an ideal dilute model.

Does higher pH change the ingredient?
Higher pH increases the salicylate fraction. This changes speciation even when total analytical acid equivalents remain the same.

Is total acid concentration the same as free-acid fraction?
No, total concentration and species distribution are different measures. Both are useful when evaluating a formulation.

Does lower pH always mean a better product?
No, tolerability, compatibility and crystallization can limit the useful window. Optimize the complete formulation for its intended purpose.

Can a gel hide a solubility failure?
A gel can hold particles in place without dissolving them. Verify the intended physical state rather than judging only bulk appearance.

Can Salicylic Acid preserve a product by itself?
Adequate preservation cannot be assumed from its presence. A finished-product microbiological strategy and relevant testing are necessary.

Can every cosmetic prototype claim to treat acne?
A therapeutic claim requires the appropriate product framework and evidence. Ingredient identity alone does not establish medicinal status or efficacy.

Are the example formulations suitable for children?
They are not children's product recommendations. Pediatric exposure requires a separate assessment and applicable regulatory review.

Is the pure powder harmless because it appears in skincare?
No, raw-material hazards require workplace controls and the actual SDS. Familiar consumer use does not remove eye, ingestion or other relevant concerns.

What does pharmaceutical grade mean?
It should identify the standard and controls claimed for the supplied material. A high purity percentage alone does not establish compendial compliance.

Is an analytical reagent automatically a certified standard?
No, a certified reference material provides a different documentation basis. Select according to the method's traceability requirements.

Why can titration and chromatography give different information?
Titration measures acidity under its method, while chromatography can provide chemical selectivity. The appropriate interpretation depends on the application and impurities of interest.

Can the acid be used in plant experiments?
It is used in controlled plant-signaling research. Species, concentration, vehicle and experimental controls determine how results should be interpreted.

Does plant research establish an approved crop treatment?
No, experimental activity does not establish agricultural authorization or crop safety. Commercial use requires separate review.

Does the melting point define a manufacturing temperature?
No, solvent compatibility and process hazards determine suitable conditions. Melting references should not become a universal heating instruction.

Which documents should a buyer request?
Request the TDS, SDS and relevant COA as a core set. Add the standard, impurity and suitability documents needed for the intended use.

How should a replacement source be qualified?
Compare analytical quality and performance in a representative process or vehicle. Use agreed acceptance criteria and controlled preparation conditions.

What information improves a quotation request?
Provide identity, intended application, grade requirements, quantity and delivery details. Include any physical-form or documentation constraints important to production.

How can Ataman Kimya assist with sourcing?
Contact Ataman Kimya to discuss the proposed grade and request available technical and batch information. Confirm specifications, availability and commercial terms for the actual offer.

SALICYLIC ACID SUPPLY FROM ATAMAN KIMYA

2-Hydroxybenzoic Acid sourcing discussions begin with the function your process needs from the material. Share whether the requirement concerns personal-care development, chemical synthesis, pharmaceutical manufacture or analytical work so that the proposed grade can be reviewed against a specific brief. Contact Ataman Kimya with the required standard, analytical limits, physical form and quantity to request a suitable proposal and available documentation.

Where a source change is planned, compare a representative sample with the established reference before approving routine production. The strongest purchasing decision connects chemical identity with measured quality, dissolution behavior and traceable supply information. That approach gives technical buyers and formulators a practical basis for selecting Salicylic Acid for a repeatable process and a well-supported finished product.